Progressive multiple sclerosis – Diagnostics – Overview of Information and Clinical Research

Diagnosing progressive multiple sclerosis requires careful evaluation by healthcare professionals, as there isn’t a single test that can confirm the condition. Instead, doctors rely on a combination of clinical observations, medical history, brain and spinal cord imaging, laboratory tests, and specialized procedures to identify the disease and rule out other conditions that may cause similar symptoms.

Introduction: Who Should Seek Diagnostic Testing

If you notice symptoms that gradually worsen over time—such as difficulty walking, muscle weakness, vision changes, numbness, or problems with balance—it’s important to seek medical attention. These symptoms might be early signs of progressive multiple sclerosis, or they could indicate another neurological condition that needs proper evaluation.^[1]

People who should consider diagnostic testing for progressive MS include those experiencing a steady decline in physical or cognitive abilities without clear periods of improvement or remission. Unlike the more common relapsing-remitting form of MS, where symptoms come and go in episodes, progressive MS typically shows a continuous pattern of worsening. This can make it harder to recognize at first, since the changes happen slowly and may seem minor in the beginning.^[4]

Most people with primary progressive MS receive their diagnosis in their 40s to 50s, although the condition can appear at any age. If you have a family member with MS or have noticed subtle changes in your ability to perform daily tasks—like climbing stairs, holding objects, or concentrating—these are signals to consult with a healthcare provider.^[1]^[5]

⚠️ Important

Progressive MS symptoms often start subtly and increase in severity over time. Because symptoms aren’t entirely obvious at first, many people delay seeking medical care. Early diagnosis is valuable, as it allows for earlier intervention and better planning for managing the condition over the long term.

Diagnostic Methods for Progressive Multiple Sclerosis

Diagnosing progressive multiple sclerosis is a complex process that involves multiple steps and several different types of testing. Your healthcare provider will gather information from various sources to build a complete picture of what’s happening in your body. This comprehensive approach helps distinguish progressive MS from other neurological conditions that may present with similar symptoms.^[1]

Medical History and Physical Examination

The diagnostic journey begins with a detailed medical history and neurological examination. Your doctor will ask about your symptoms, when they started, how they’ve changed over time, and whether you’ve experienced any periods where symptoms improved or worsened. This conversation is crucial because the pattern of symptom progression helps differentiate primary progressive MS from other types of MS and from conditions like stroke, vitamin deficiencies, or infections.^[4]

During the neurological examination, which is a series of tests to assess how well your nervous system is functioning, your doctor will evaluate your muscle strength, coordination, balance, reflexes, vision, and sensation. They may ask you to walk, move your eyes in different directions, or perform tasks that test your memory and thinking abilities. These physical assessments help identify areas of your nervous system that may be affected by the disease.^[9]

Magnetic Resonance Imaging (MRI)

An MRI scan, which uses powerful magnets and radio waves to create detailed images of the inside of your body, is one of the most important diagnostic tools for MS. The MRI can reveal areas of damage on your brain and spinal cord where the protective covering around nerve fibers, called myelin, has been destroyed. These damaged areas appear as spots or patches on the scan, often called lesions or scars.^[1]

In progressive MS, MRI findings may show widespread damage across the brain and spinal cord. Doctors look for patterns of injury that are characteristic of MS, including lesions in specific locations. The MRI can also help rule out other conditions like tumors, strokes, or structural problems that might cause similar symptoms. Sometimes, a contrast dye is injected during the MRI to highlight areas of active inflammation, although this is less common in progressive MS compared to the relapsing-remitting form.^[4]

Lumbar Puncture (Spinal Tap)

A lumbar puncture, also called a spinal tap, is a procedure where a small amount of cerebrospinal fluid (the liquid that surrounds your brain and spinal cord) is collected using a thin needle inserted into the lower back. This test is performed to look for specific markers of MS in the fluid. One of these markers is called oligoclonal bands, which are proteins commonly found in people with MS, though they can also appear in other conditions involving inflammation of the brain or spinal cord.^[1]^[10]

The presence of oligoclonal bands can provide evidence that inflammation is occurring in your central nervous system, which supports an MS diagnosis. However, this test alone cannot confirm MS, which is why it’s used alongside other diagnostic methods. The procedure takes about 30 to 45 minutes and is typically done in a hospital or clinic setting. You may experience a headache afterward, but this usually resolves within a few days.^[4]

Blood Tests

Although there is no blood test that can diagnose MS directly, blood tests play an important role in the diagnostic process. They help rule out other conditions that can mimic MS symptoms, such as vitamin B12 deficiency, Lyme disease, lupus, or thyroid disorders. By excluding these other possibilities, doctors can be more confident in an MS diagnosis.^[1]^[9]

Your doctor may order a panel of blood tests to check for infections, autoimmune markers, vitamin levels, and signs of inflammation. This process of elimination is essential because many neurological conditions share overlapping symptoms, and accurate diagnosis requires careful differentiation.^[4]

Optical Coherence Tomography (OCT)

An optical coherence tomography scan is a painless imaging test that examines the nerves at the back of your eye, called the retina. MS can damage the optic nerve, which connects your eye to your brain, and OCT can detect this damage even when it doesn’t cause noticeable vision problems. The test uses light waves to take cross-sectional pictures of the retina, allowing doctors to measure the thickness of nerve layers.^[1]

Thinning of the nerve fiber layer in the retina is common in people with MS and can serve as additional evidence supporting the diagnosis. The OCT test is quick, non-invasive, and similar to having a photograph taken of your eye. It’s increasingly used as part of the comprehensive evaluation for MS.^[10]

Clinical Observation and Diagnosis Criteria

Diagnosing primary progressive MS often requires clinical observation over time. To confirm a diagnosis of PPMS, doctors look for specific criteria: you must have at least one year of consistent worsening of neurological function, and you must meet at least two additional criteria from a list that includes specific types of brain or spinal cord lesions on MRI, or the presence of oligoclonal bands in cerebrospinal fluid.^[4]

This means that sometimes diagnosis cannot be made immediately after your first visit. Your doctor may need to monitor your symptoms over several months to observe the pattern of progression. This can feel frustrating when you’re seeking answers, but it’s necessary to ensure an accurate diagnosis. The time element is particularly important because progressive MS is defined by gradual worsening that continues for at least six months to a year without periods of remission.^[5]

Diagnostics for Clinical Trial Qualification

If you’re considering participating in a clinical trial for progressive MS, you’ll need to undergo specific tests and evaluations to determine whether you meet the trial’s enrollment criteria. Clinical trials have strict requirements to ensure that participants are appropriate for the experimental treatment being studied and that results are scientifically valid.^[8]

Standard Assessment Tools

Most clinical trials for progressive MS use standardized measures to assess disability level and disease progression. The Expanded Disability Status Scale (EDSS) is the most widely used tool. It rates disability from 0 (no symptoms) to 10 (death from MS) based on your ability to walk and the function of various body systems. Many trials require participants to have a specific EDSS score range to ensure they have measurable disability that isn’t too mild or too severe.^[11]

The Multiple Sclerosis Functional Composite (MSFC) is another assessment used in clinical trials. This test measures three key areas: walking speed (using a timed 25-foot walk test), hand dexterity (using a 9-hole peg test where you place and remove pegs from holes), and cognitive processing speed (using a paced auditory addition test). These measurements provide objective data about your functional abilities and help researchers determine if a treatment is working.^[11]

MRI Requirements

Clinical trials typically require baseline MRI scans before you can enroll, and then repeated MRI scans at specific intervals throughout the study. Researchers examine these scans for new or enlarging lesions, areas of active inflammation (shown by contrast enhancement), and measurements of brain atrophy, which is the loss of brain tissue volume over time. Brain atrophy correlates with disability progression and is an important endpoint in progressive MS trials.^[11]

The MRI protocol used in clinical trials is often more detailed and standardized than what you might receive in routine clinical care. The images are analyzed using specialized software to measure very small changes in brain volume that wouldn’t be visible to the naked eye.^[8]

Biomarker Testing

Some clinical trials measure levels of neurofilament light chain (NfL) in your blood or cerebrospinal fluid. Neurofilaments are proteins that form part of the structural framework of nerve cells. When nerve cells are damaged, these proteins leak into the surrounding fluid and can be detected in blood or cerebrospinal fluid samples. Higher levels of NfL indicate more active nerve damage and can serve as a marker of disease activity in progressive MS.^[11]

This type of biomarker testing is still relatively new but is becoming more common in clinical trials. It provides researchers with another way to measure whether a treatment is slowing down the neurodegenerative process that drives progressive MS.^[3]

⚠️ Important

Clinical trial eligibility criteria are designed for research purposes and may be more stringent than the criteria used for clinical diagnosis. You might have progressive MS but not qualify for a particular trial if your disease is too mild, too advanced, or if you have other health conditions that could interfere with the study. Each trial has unique requirements, so being ineligible for one trial doesn’t mean you can’t participate in others.

Confirmation of Disease Type

Clinical trials for progressive MS often require clear documentation that you have either primary progressive MS or secondary progressive MS, rather than relapsing-remitting MS. This distinction is made based on your medical history, pattern of symptoms over time, and evidence from MRI scans. You may need to provide medical records spanning several years to demonstrate the progressive nature of your condition.^[4]

Some trials specifically focus on people with primary progressive MS, while others include both primary and secondary progressive forms. The trial team will carefully review all your diagnostic information to confirm you meet their specific definition of progressive MS before you can enroll.^[8]

Prognosis and Survival Rate

Prognosis

The outlook for people living with progressive multiple sclerosis varies significantly from person to person. Progressive MS is characterized by a gradual worsening of symptoms over time, with the rate of progression being unpredictable and highly individual. Some people experience slow, steady decline over many years, while others may see more rapid changes in their abilities.^[3]

Several factors can influence how the disease progresses. The age at which symptoms begin, the specific areas of the nervous system affected, and how quickly disability accumulates in the early years can all provide clues about future disease course. Generally, people diagnosed with primary progressive MS tend to experience steady worsening from the beginning without periods of improvement, while those who develop secondary progressive MS after an initial relapsing-remitting phase may have accumulated some disability before entering the progressive stage.^[5]

While progressive MS leads to increasing disability over time, many people continue to maintain a good quality of life with appropriate management and support. Modern disease-modifying therapies have shown promise in slowing disease progression, and treatments for managing symptoms have improved dramatically. Complications that can affect prognosis include muscle tightness, vision loss, bladder control difficulties, sexual dysfunction, memory problems, and mood changes.^[1]

Survival rate

Multiple sclerosis, including its progressive forms, is not generally considered a fatal disease. Research has shown that people with MS live, on average, to be about 75.9 years old, compared to 83.4 years for people without MS. This represents a gap of approximately 7 to 8 years. Importantly, this gap has narrowed considerably in recent decades due to better treatments and earlier diagnosis.^[15]

While MS itself rarely causes death directly, people with progressive MS may be more vulnerable to complications that can affect life expectancy. These complications include heart disease, pneumonia, pressure ulcers from reduced mobility, and urinary tract infections. The risk of these complications varies depending on the severity of disability and how well symptoms are managed.^[15]

It’s important to note that about 10% to 15% of all people diagnosed with MS have the primary progressive form, and after an average of 19 years, approximately 70% of people who initially had relapsing-remitting MS develop secondary progressive MS. However, advances in treatment are changing these statistics, particularly for those who receive early and effective disease-modifying therapy.^[3]^[5]

#1 Clinical Trials Search in Europe

Progressive multiple sclerosis – Diagnostics

Introduction: Who Should Seek Diagnostic Testing